Comparative diagnostic accuracy of panic provocation tests: A meta-analysis.

J Psychiatr ResMay 20, 2026 (epub)
Clinical ResearchPsychiatry

Umit Tural, Sara Rose Shannon, Dan V Iosifescu

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis evaluated the diagnostic accuracy of various panic provocation tests in a population of 5693 participants across 123 studies. Sodium lactate infusion demonstrated the highest pooled diagnostic odds ratio (DOR) of 24.77, indicating superior diagnostic discrimination for panic disorder compared to healthy controls. The study utilized random-effects meta-analyses with Hartung-Knapp adjustment.

Key findings

  • Sodium lactate infusion had the highest pooled DOR of 24.77 (95% CI 19.03-32.25).
  • Isoproterenol showed a DOR of 18.85 (95% CI 12.39-28.66).
  • Cholecystokinin tetrapeptide (CCK-4) had a DOR of 15.03 (95% CI 7.83-28.84).
  • Breath holding, fenfluramine, and flumazenil did not show significant discriminative ability.

Why it matters

Understanding the diagnostic accuracy of panic provocation tests is crucial for clinicians in accurately diagnosing panic disorder. This meta-analysis highlights the effectiveness of specific tests, particularly sodium lactate infusion, which may enhance diagnostic precision in clinical practice.

Source

Published in J Psychiatr Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.